TVRD vs SIF Comparison

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

SIFCO Industries Inc produces forgings, sub-assemblies, and machined components for the Aerospace and Energy markets. Its services include forging, heat treating, machining, surface treatment, non-destructive testing, and sub-assembly of forged components. The company manufactures envelopes and precision forgings, as well as rough and finished machined parts, serving OEMs, Tier 1 and Tier 2 suppliers, and aftermarket providers across Aerospace, Defense, Energy, and Commercial Space. Its Products are made from steel, high-temperature alloys, nickel alloys, titanium, and aluminum, and include components for aircraft and industrial gas turbine engines, airframe structures, landing gear, wheels and brakes, helicopter rotating parts, and other commercial and industrial applications.